Browsing
     by title


0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

or enter first few letters:   
OK
Peer Reviewed
See detailLes prestations des salariés en heures supplémentaires. Résultats d'une enquête.
Ginsburgh, Victor; Pestieau, Pierre ULg; Perelman, Sergio ULg

in Cahiers Economiques de Bruxelles (1986), (112), 109-125

Detailed reference viewed: 15 (4 ULg)
Peer Reviewed
See detailPresurgical Octreotide Treatment in Acromegaly
Stevenaert, Achille ULg; Beckers, Albert ULg

in Acta Endocrinologica (1993), 129(1), 18-20

The effects of octreotide pretreatment before surgery were assessed in 48 acromegalic patients who underwent trans-sphenoidal surgery to remove pituitary adenoma, and compared with 107 patients who did ... [more ▼]

The effects of octreotide pretreatment before surgery were assessed in 48 acromegalic patients who underwent trans-sphenoidal surgery to remove pituitary adenoma, and compared with 107 patients who did not receive octreotide before surgery. Pretreated patients received octreotide 100 micrograms, thrice daily for 3 to 6 weeks (group 1), or 100 to 500 micrograms, thrice daily for 3 to 39 months (group 2). Total remission of symptoms was seen in 54%. Partial remission of symptoms occurred in 39%. Octreotide pretreatment reduced plasma GH levels by > or = 50% in all patients. GH levels were reduced to < 2 micrograms/1 in 3/14 group 1 cases and 13/34 group 2 cases. Tumour shrinkage occurred in 56.5% of patients. Marked tumour shrinkage (> 25%) occurred in more group 2 patients (10/32 vs 1/14). The tumour was soft in 39 patients, firm in 6 and hard in 3 cases. Soft consistency aided surgical removal of adenomas. Remission was greater in enclosed adenomas than in invasive tumours in both octreotide pretreated and nonpretreated acromegalics (76 vs 30%). Remission was more likely if the adenoma was less than 16 mm. Remission rate was significantly greater (p < 0.05) in all octreotide pretreated than in untreated patients for enclosed adenoma, but not for invasive adenoma. Octretide pretreatment can be recommended for three to four months prior to surgery. [less ▲]

Detailed reference viewed: 21 (0 ULg)
See detailPresurgical Octreotide Treatment in Acromegaly
Beckers, Albert ULg

Scientific conference (1992, August 30)

Detailed reference viewed: 1 (0 ULg)
See detailPresurgical Octreotide Treatment in Acromegaly
Beckers, Albert ULg

Scientific conference (1991, October)

Detailed reference viewed: 2 (0 ULg)
See detailPresurgical Octreotide Treatment in Acromegaly
Beckers, Albert ULg

Scientific conference (1994, April 08)

Detailed reference viewed: 2 (0 ULg)
See detailPresurgical Octreotide Treatment in Acromegaly
Beckers, Albert ULg

Scientific conference (1994, April)

Detailed reference viewed: 1 (0 ULg)
See detailPresurgical octreotide treatment in acromegaly
Stevenaert, Achille ULg; Beckers, Albert ULg

in 5th International Pituitary congress - abstract book (1998)

Detailed reference viewed: 4 (0 ULg)
See detailPresurgical Octreotide Treatment in Acromegaly
Stevenaert, Achille ULg; Beckers, Albert ULg

in Acta Neurochirurgica (1995), 133

Detailed reference viewed: 1 (0 ULg)
See detailPresurgical octreotide treatment in acromegaly
Stevenaert, Achille ULg; Beckers, Albert ULg

in 3rd International pituitary congress - Abstract book (1993)

Detailed reference viewed: 2 (0 ULg)
Peer Reviewed
See detailPresurgical octreotide treatment in acromegaly
Stevenaert, Achille ULg; Beckers, Albert ULg

in Journal of Endocrinological Investigation (1993), 16(1-8), 137

Detailed reference viewed: 1 (0 ULg)
See detailPresurgical Octreotide Treatment in Acromegaly : does it improve surgical cure rate?
Stevenaert, Achille ULg; Lenelle, Jacques ULg; Martin, Didier ULg et al

in 10th European Congress of Neurosurgery - Abstract book (1995)

Detailed reference viewed: 6 (0 ULg)
Peer Reviewed
See detailPresurgical octreotide treatment in acromegaly.
Stevenaert, Achille ULg; Harris, A. G.; Kovacs, K. et al

in Metabolism : Clinical and Experimental (1992), 41(9 Suppl. 2), 51-8

The aim of this study was to determine the role of octreotide administration in acromegalic patients as a preparation for selective adenomectomy using transsphenoidal route. Octreotide was administered ... [more ▼]

The aim of this study was to determine the role of octreotide administration in acromegalic patients as a preparation for selective adenomectomy using transsphenoidal route. Octreotide was administered for 3 to 6 weeks before surgery in 12 patients and for 4 to 39 months in 25 patients. The clinical response was judged as excellent or good in 10 of 12 patients from group I and in 23 of 25 patients from group II. Marked reduction (ie, greater than 50% of initial values) in serum growth hormone (GH) levels was seen in all patients, with levels to less than 5 micrograms/L in 68% of patients and less than 2 micrograms/L in 27%. Insulin-like growth factor 1 (IGF-1) levels decreased to within normal limits in half the cases. During long-term treatment, an escape phenomenon could be seen. Varying degrees of tumor shrinkage were seen in more than 50% of cases. During surgery, with regard to the relative ease or difficulty in removing the tumor, the consistency of the tumor and the separation of normal from pathological tissue, no significant difference was observed between patients given octreotide and those from control series. Morphological changes in adenomatous tissue were rather small. The surgical outcome was similar in the pretreated series as in the control series, except in enclosed adenomas, which showed a tendency to a higher success rate. Since octreotide improves both the clinical condition and hormonal parameters and induces varying degrees of tumor shrinkage, it is potentially useful as an adjunct to surgery. Morphological data suggest that octreotide exercises a functional inhibitory effect on GH release. [less ▲]

Detailed reference viewed: 8 (1 ULg)
Full Text
Peer Reviewed
See detailPresurgical Octreotide: Treatment in Acromegaly
Stevenaert, Achille ULg; Beckers, Albert ULg

in Metabolism : Clinical and Experimental (1996), 45(8 Suppl. 1), 72-4

One hundred seventy-two acromegalics who were operated on using the trans-sphenoidal approach underwent long-term follow-up evaluation. Sixty-four received 100 micrograms octreotide subcutaneously three ... [more ▼]

One hundred seventy-two acromegalics who were operated on using the trans-sphenoidal approach underwent long-term follow-up evaluation. Sixty-four received 100 micrograms octreotide subcutaneously three times daily: for 3 to 6 weeks before surgery in 14 patients (group 1); and for 3 to 9 months in 41 and for 13 to 39 months in nine (n = 50, group 2). In 18 group 2 patients, the dose was increased stepwise to 500 micrograms three times daily because of incomplete suppression of growth hormone (GH)/insulin-like growth factor-1 (IGF-1). Tumor shrinkage was seen in 60% within 3 weeks, being nearly maximal by 3 to 4 months. More group 2 patients had greater than 25% tumor shrinkage (14 of 48 v 1 of 14 in group 1). Clinical response was excellent or good in 89%. Decrease in soft-tissue swelling and weight loss, and improved vitality, performance, carbohydrate metabolism, and cardiovascular function, facilitated anesthetic and surgical management; tumor removal was easy in virtually all cases. In all 64 patients, GH levels decreased by > or = 50%, and to < 2 micrograms/L in three of 14 patients initially and 25 of 50 patients after more prolonged treatment. IGF-1 levels decreased to normal in seven of 14 group 1 and 31 of 50 group 2 patients. Light and electron microscopy showed that adenomatous tissue exposed to octreotide had lysosomal accumulation, amyloid deposition, mild to moderate perivascular fibrosis, and moderate size reduction in both cytoplasmic and nuclear areas, with virtually no cellular complications. Remission with enclosed adenomas was greater (p < .05) than for the 108 patients not treated with octreotide; there was no difference for invasive adenomas. Octreotide use for 3 to 4 months before surgery can be recommended. [less ▲]

Detailed reference viewed: 32 (1 ULg)
See detailPresurgical Sandostatin treatment in acromegaly.
Stevenaert, Achille ULg; Beckers, Albert ULg

Conference (1991)

Detailed reference viewed: 3 (0 ULg)